Our products and services are essential components for the research, development and production of new generation medicines as for example vaccines, immuno-oncology therapies, and protein replacement treatments.
Discover our latest initiatives, technology advancements, expansion plans, and our ongoing commitment to research and development of cutting-edge solutions for Cell & Gene Therapies and Nucleic Acids.
RNA-based technologies include messenger RNA (mRNA), RNA interference (RNAi), and the emerging circular RNA (circRNA), each offering a unique pathway to address genetic and protein-level diseases effectively.
read moreTherapeutic innovations are as diverse as the challenges they address—ranging from gene and cell therapies to mRNA-based treatments and next-generation biologics.
read moremRNA technology has emerged as a transformative force in the biopharmaceutical industry, enabling groundbreaking therapies and vaccines, including those for COVID-19.
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to Advanced Therapies Week 2025 in Dallas, TX
read moreAdvanced therapies, particularly cell and gene therapies, are ushering in a new era of personalized medicine, offering hope for patients with previously untreatable diseases.
read moreWhat is the perfect recipe that delivers the maximum result?
read moreWhat is the perfect recipe that delivers the maximum result?
read moreWorking in a Biotech Manufacturing Organization means joining a team of talented professionals focused on innovation, continuous growth, and a shared mission to improve lives.
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to 12th International mRNA Health Conference 2024 in Boston, MA
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to 1st Annual Meeting AMM ASCENT in Boston, MA
read moreAnemocyte offers plasmid DNA (pDNA) manufacturing covering R&D, High Quality and GMP needs providing solutions that support every stage of therapy development while ensuring rigorous quality and traceability.
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to European Society of Gene & Cell Therapy 2024 in Rome, Italy
read more
Anemocyte S.r.l. Single Shareholder Private Limited-Liability Company
Via R. Lepetit, 34 21040 Gerenzano (VA) Italy | Ph: +39 02 99372311 – Fax: +39 02 99372313 | Anemocyte Inc. 1221 Brickell Avenue, Suite 1160 Miami FL 33131
VAT number: 12914940155 | Share capital € 530.000,00 fully paid | R.E.A. 276961
